OESO-SEMPIRE 17th World Conference | Esophagus 2026 Versailles | June 14-17, 2026

GI Clinical Pharmacology & Therapeutics

Tuesday June 16, 9:00 – 10:30 pm
Auditorium Lulli

Chairs: Carmelo Scarpignato (Malta) – C. Prakash Gyawali (USA)
 

I – Acid Suppression: Present and Future

  1. Acid Suppression: Limitations of the Current Antisecretory Drugs. Why do PPIs fail in some patients, and what are the true boundaries of acid suppression? – Justin Wu (Hong Kong)
  2. Potassium-competitive Acid Blockers (P-CABs): A Step Forward in Acid Suppression. Do they really represent a paradigm shift or just an incremental advance? – Carmelo Scarpignato (Malta)
  3. P-CABs for GERD: When and How. Patient profiles, timing, and switching strategies. – Ronny Fass (USA)
  4. Alginate-containing Formulations: Before, With, or After PPIs? Optimizing the synergy between mechanical and pharmacologic acid control. – Serhat Bor (Turkey)

    II – Mucosal Protection and Beyond 
  5. Mucosal Protective Compounds for GERD: How Much Are They Effective? Evidence and clinical relevance of sucralfate, hyaluronic acid–chondroitin sulfate, and similar agents. – Daniel Sifrim (UK)
  6. The Status of Pepsin Inhibitors for PPI-Refractory GERD and LPR. A promising approach or another dead end? – Nikki Johnston (USA)

    III – Motility & Neuromodulation
  7. GI Prokinetics: Which Role in GERD? From metoclopramide to acotiamide—any real progress? – José María Remes Troche (Mexico)
  8. When Are Neuromodulators Indicated in GERD? Functional heartburn, reflux hypersensitivity, and esophageal perception. – C. Prakash Gyawali (USA)

    IV – Eosinophilic Esophagitis (EoE)
  9. PPIs or Steroids for EoE: Alone or in Combination? Balancing efficacy, safety, and long-term management. – Nirmala Gonsalves (USA)
  10. EoE: When to Start Biologic Therapy and How? Current position of anti–IL-13/IL-4 agents and future perspectives. – Nicola De Bortoli (Italy)

    V – Motor Disorders & New Frontiers
  11. Smooth Muscle Relaxants for Achalasia: Still a Bridge Treatment? Are pharmacologic options still relevant in the POEM era? – Mark Fox (Switzerland)
  12. Long-term Safety and Pharmacogenetics of Acid Suppression. Are we ready for tailored therapy and precision acid suppression? – Walter W. Chan (USA)
  13. Reflux Inhibitors: A Promise Unfulfilled or a Niche Therapy? TargeQng TLESRs: TranslaQonal Failures and Clinical Residues – Marcelo Vela (USA)